AR102108A1 - Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados - Google Patents

Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados

Info

Publication number
AR102108A1
AR102108A1 ARP150103125A ARP150103125A AR102108A1 AR 102108 A1 AR102108 A1 AR 102108A1 AR P150103125 A ARP150103125 A AR P150103125A AR P150103125 A ARP150103125 A AR P150103125A AR 102108 A1 AR102108 A1 AR 102108A1
Authority
AR
Argentina
Prior art keywords
dry powder
formulation
weight
inhalate
combined active
Prior art date
Application number
ARP150103125A
Other languages
English (en)
Inventor
Soo Woo Jong
Hyun Park Jae
Min Yoon Young
Jun Cho Hyuk
Soo Kim Kyeong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR102108A1 publication Critical patent/AR102108A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un polvo seco para una formulación para inhalar y una formulación para inhalar que incluye el polvo seco. El polvo seco incluye: al menos dos principios activos combinados seleccionados a partir del grupo constituido por salmeterol o una de sus sales farmacéuticamente aceptables, tiotropio o una de sus sales farmacéuticamente aceptables y fluticasona o una de sus sales farmacéuticamente aceptables; y un diluyente, como complejo de lactosa, donde el diluyente incluye entre aproximadamente un 0.1% en peso y aproximadamente un 50% en peso de polvo micronizado que tiene un diámetro de partícula promedio (X₅₀) igual o inferior a aproximadamente 30 mm en función del peso total del diluyente, de modo que la estabilidad de al menos uno de los principios activos es superior a la de un polvo seco que tiene un contenido en polvo micronizado superior a un 50% en peso. Método.
ARP150103125A 2014-09-30 2015-09-29 Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados AR102108A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20140132006 2014-09-30

Publications (1)

Publication Number Publication Date
AR102108A1 true AR102108A1 (es) 2017-02-01

Family

ID=55630875

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103125A AR102108A1 (es) 2014-09-30 2015-09-29 Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados

Country Status (5)

Country Link
KR (1) KR20160038767A (es)
AR (1) AR102108A1 (es)
TW (1) TW201618759A (es)
UY (1) UY36336A (es)
WO (1) WO2016052897A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
JP2007528889A (ja) * 2004-03-12 2007-10-18 シプラ・リミテッド 吸入製剤
TR201000681A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법

Also Published As

Publication number Publication date
WO2016052897A1 (en) 2016-04-07
TW201618759A (zh) 2016-06-01
KR20160038767A (ko) 2016-04-07
UY36336A (es) 2016-04-01

Similar Documents

Publication Publication Date Title
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
UY36275A (es) Compuestos aminopirimidinilo
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
PH12017500481A1 (en) Novel soluble guanylate cyclase activators and their use
EA201690888A1 (ru) Новые гетероциклические соединения
BR112018011376A2 (pt) composição farmacêutica que compreende um inibi-dor de urat1 potente
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
BR112017012435A2 (pt) guindaste sobre rodas e métodos de autodesmontagem e automontagem para pernas de suporte do mesmo
CL2016000300A1 (es) Métodos terapéuticos
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
BR112017004948A2 (pt) formulação farmacêutica.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
AR102108A1 (es) Polvo seco para una formulación para inhalar que tiene una estabilidad mejorada de los principios activos combinados
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
EA201500694A1 (ru) Монолитная лекарственная форма для модифицированного высвобождения комбинации активных ингредиентов
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
CO2017000354A2 (es) Desmopresina estabilizada

Legal Events

Date Code Title Description
FB Suspension of granting procedure